Clinical trials: SARS
COVID-19
Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose…
- Trial name
- MOSAIC (NCT04894435)
- Testing
- mRNA-1273 SARS-CoV-2 vaccine, BNT162b2, ChAdOx1-S [recombinant]
- Where
- 8 sites in Canada
- Volunteers
- 669 people, healthy volunteers welcome
- Sponsor
- Canadian Immunization Research Network
COVID-19
Use of Multiple Doses of Convalescent Plasma in Mechanically Intubated Patients With COVID-19
This study will assess the feasibility and safety of administering multiple doses of convalescent plasma to Covid-19 positive patients admitted to the Intensive Care Unit (ICU) receiving mechanical ventilation.
- Trial name
- NCT05595538
- Testing
- Multiple doses of anti-SARS-CoV-2 Convalescent Plasma
- Where
- Panama
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospital Regional Dr. Rafael Estévez
Hydroxychloroquine, Antimalarials
Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals
This study will investigate the security and efficacy of a daily low dose of hydroxychloroquine and Bromhexine, in preventing the development of the disease from COVID-19 in Health Care Workers at a National Institute of Health…
- Conditions
- Hydroxychloroquine, Antimalarials, Enzyme Inhibitors, Antirheumatic Agents
- Trial name
- ELEVATE (NCT04340349)
- Testing
- Hydroxychloroquine Sulfate, Bromhexine 8 MG
- Where
- Mexico
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- Instituto Nacional de Rehabilitacion
COVID-19
Study of "Sputnik Lite" for the Prevention of COVID-19 With Altered Antigenic Composition.
Safety, reactogenicity and immunogenicity study of the drug "Sputnik Lite" for the prevention of coronavirus infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of adult volunteers.
- Trial name
- NCT06057025
- Testing
- "Sputnik Lite" vaccine for the prevention of COVID-19 with altered antigenic composition
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Coronavirus, SARS-CoV-2
Rutgers COVID-19 Cohort Study
Our long-term goal is to protect the health care workforce (HCW) caring for SARS-CoV-2-infected patients, their families, communities, and the general population.
- Trial name
- NCT04336215
- Testing
- Non-Interventional
- Where
- 7 sites in United States
- Volunteers
- 829 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
SARS CoV 2 Infection
Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.
To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and…
- Trial name
- Sisonke Boost (NCT05148845)
- Testing
- Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S
- Where
- 31 sites in South Africa
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Wits Health Consortium (Pty) Ltd
Covid19, SARS-CoV-2 Infection
A Study to Determine Safety and Immunogenicity of the Candidate COVID-19 Vaccine AZD1222 Delivered by Aerosol in Healthy Adult Volunteers
This study will test the COVID-19 vaccine candidate AZD1222 to investigate its safety, tolerability and capability of boosting immune responses both in the blood and the lung when administered to the respiratory tract, in…
- Trial name
- COVAXAER01 (NCT05007275)
- Testing
- 1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Vaccine Reaction
Antibody Response and Longevity Post SARS-CoV-2 Vaccine (SARS-AB)
Longitudinal study on healthy subjects to investigate the longevity of the antibody response to the Pfizer-BioNTech COVID-19 vaccine.
- Trial name
- SARS-AB (NCT05515081)
- Testing
- blood sample collection
- Where
- Italy
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Camillo, Venezia, Italy
Sars-CoV2, Coronavirus Infection
Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)
Professionals and residents of nursing homes are one of the most vulnerable groups in this public health crisis of COVID-19, since they have the highest rate of positives for COVID-19, despite the restriction measures carried…
- Conditions
- Sars-CoV2, Coronavirus Infection, Prevention & Control, Nursing Home
- Trial name
- PREVICHARM (NCT04400019)
- Testing
- Hydroxychloroquine Only Product in Oral Dose Form
- Volunteers
- 1,930 people, healthy volunteers welcome
- Sponsor
- University of Malaga
COVID-19 Disease, SARS Pneumonia
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
This prospective, single-center, randomized, placebo-controlled, observer-blind Phase 1/2 study includes two separate parts. Part 1 is a first-in-human, Phase 1 study designed to evaluate the safety, tolerability and…
- Conditions
- COVID-19 Disease, SARS Pneumonia, Pneumonia, Viral, COVID-19 Vaccine
- Trial name
- NCT04830800
- Testing
- COVIVAC, Phosphate-buffered saline
- Where
- Vietnam
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Institute of Vaccines and Medical Biologicals, Vietnam
COVID - 19, SARS CoV-2
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19
This is a Phase 1a, single-country, single-centre, single-blinded, COV2 vaccine formulation randomized trial designed to investigate and compare the safety and immunogenicity of two COV2 vaccine formulations.
- Trial name
- NCT07416539
- Testing
- COVID-19 Vaccines
- Where
- Finland
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Rokote Laboratories Finland Oy
COVID-19, SARS-COV-2 Infection
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect…
- Trial name
- NCT07300839
- Testing
- BNT162b2 Vaccine
- Where
- 196 sites in United States
- Volunteers
- 5,240 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19
Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial
Since the emergence of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen in late 2019, millions of people around the world have fallen ill and died from coronavirus disease 2019 (COVID-19), with…
- Trial name
- NCT05343871
- Testing
- Sinovac, AZD1222, BNT162b2
- Where
- 2 sites in Brazil, Pakistan
- Volunteers
- 2,354 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Coronavirus Disease (COVID-19)
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection.
- Trial name
- MOVe-AHEAD (NCT04939428)
- Testing
- Molnupiravir
- Where
- 226 sites in United States, Argentina and 21 more
- Volunteers
- 2,441 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
COVID-19, SARS CoV 2 Infection
Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults
This clinical trial is designed to assess the safety, tolerability and immunogenicity of a single dose of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 vaccines as a booster dose, given at least 3 months after receipt of a previous…
- Trial name
- NCT05605470
- Testing
- ChulaCov19 BNA159 vaccine (50 mcg), Pfizer/BNT vaccine (30 mcg), COMVIGEN (ChulaCov19 BNA159.2) vaccine (50 mcg)
- Where
- 5 sites in Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Technovalia, Pty Ltd
COVID-19 Respiratory Infection
Cardiovascular Disease and Outcomes Among Patients With SARS-CoV-2 Infection (COVID-19)
The coronavirus disease of 2019 (COVID-19) has affected over 2.4 million individuals worldwide and has resulted in >171,000 deaths. Cardiovascular disease (CVD) is an important contributor to death in these patients.
- Trial name
- NCT05085262
- Testing
- Bloodwork, Echocardiogram, PET/MRI, Bloodwork, Echocardiogram, MRI
- Where
- Canada
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Prevention of COVID-19
Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland
A study to assess, in a two-arm open-label cluster randomized clinical trial, the efficacy of a 5-day course of LPV/r treatment in preventing COVID-19 in asymptomatic individuals exposed to a SARS-CoV-2 documented index patient…
- Trial name
- COPEP (NCT04364022)
- Testing
- Lopinavir/ritonavir
- Where
- 4 sites in Brazil, Switzerland
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Calmy Alexandra
SARS-CoV-2
Evaluation of Quickly Diagnostic Saliva Tests for SARS-CoV-2
Coronavirus disease 2019 or COVID-19 is a highly contagious infectious disease. Symptoms of the disease are non-specific (fever, cough, dyspnea and fatigue), common with many seasonal viruses, which complicates the diagnosis.
- Trial name
- EasyCoV (NCT04337424)
- Testing
- Sampling salivary
- Where
- France
- Volunteers
- 627 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
COVID-19, SARS-CoV-2 Infection
Study to Compare the Immunogenicity and Safety of 3 Lots of NVX-CoV2373 in Adults
This is a randomized, Phase 3 study comparing the immunogenicity and safety of 3 different lots of Novavax vaccine with Matrix-M™ adjuvant (NVX-CoV2373).The study will enroll approximately 900 previously vaccinated adults 18 to…
- Trial name
- NCT05463068
- Testing
- NVX-Cov2373
- Where
- 30 sites in United States
- Volunteers
- 911 people, healthy volunteers welcome
- Sponsor
- Novavax
SARS-CoV2 Infection
The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions
This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public Health that provides take-home saliva testing kits in schools.
- Trial name
- NCT05055492
- Testing
- Take home saliva kits
- Where
- Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Hospital for Sick Children
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.